Prateek Sanghera, MD
Nephrology · Las Vegas, NVNPI 1316232820
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,138 of the $7,176 with a category attached, or 85.5%. It is spread thinly across 30 manufacturers, the largest accounting for just 17.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,177, 7.4 times the $294 reported in 2019.
Across 308 payments — averaging $23.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Merit Medical Systems Inc$919
- Amgen$876
- Vifor Pharma, Inc.$707
- Medtronic$629
- Otsuka America Pharmaceutical, Inc.$507
- plus $2K from 24 others
Across 6 payments — averaging $6370.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$38K
What the payments were for
- Consulting fees$76011%
- Food & beverage$6,13886%
- Education$2784%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 41 | $1,261 |
| Merit Medical Systems Inc | 3 | $919 |
| Amgen(2 entities) | 39 | $876 |
| Vifor Pharma, Inc. | 50 | $707 |
| Medtronic | 16 | $629 |
| Otsuka America Pharmaceutical, Inc. | 39 | $507 |
| Bayer | 15 | $294 |
| Fresenius USA Marketing, Inc. | 24 | $278 |
| GSK | 15 | $252 |
| Calliditas Therapeutics US Inc. | 7 | $215 |
| Travere Therapeutics, Inc. | 7 | $159 |
| Lilly USA, LLC | 7 | $133 |
| Novo Nordisk | 6 | $106 |
| ANI Pharmaceuticals, Inc. | 3 | $83 |
| Bard Peripheral Vascular, Inc. | 4 | $81 |
| OPKO Pharmaceuticals, LLC | 4 | $78 |
| Pharmacosmos Therapeutics Inc. | 4 | $78 |
| Ardelyx, Inc. | 3 | $64 |
| Boehringer Ingelheim | 3 | $63 |
| Akebia Therapeutics Inc | 3 | $61 |
| Kyowa Kirin, Inc. | 3 | $57 |
| Aurinia Pharma U.S., Inc. | 2 | $51 |
| Daiichi Sankyo Inc. | 2 | $50 |
| Novartis | 2 | $44 |
| Laminate Medical Technologies Inc. | 1 | $38 |
| Mallinckrodt Hospital Products Inc. | 1 | $26 |
| Inari Medical, Inc. | 1 | $20 |
| Argon Medical Devices, Inc. | 1 | $18 |
| Cormedix Inc. | 1 | $14 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ELLIPSYS VASCULAR ACCESS SYSTEM$400
- LOKELMA$137
- Parsabiv$125
- TARPEYO$103
How this compares
$7,176 in reported general payments places this provider in the 85th percentile of 125 nephrology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XphozahTenapanor Hcl | 16 | $45,931 |
| DapagliflozinDapagliflozin Propanediol | 30 | $33,498 |
| VelphoroSucroferric Oxyhydroxide | 17 | $31,744 |
| VeltassaPatiromer Calcium Sorbitex | 15 | $24,472 |
| FarxigaDapagliflozin Propanediol | 17 | $18,114 |
| Calcitriol | 137 | $3,937 |
| Vitamin D2Ergocalciferol (Vitamin D2) | 33 | $409 |
| Losartan Potassium | 54 | $382 |
| Furosemide | 35 | $281 |
| Nifedipine ErNifedipine | 16 | $193 |
| Carvedilol | 20 | $181 |
| Tamsulosin Hcl | 15 | $114 |
| Amlodipine Besylate | 13 | $112 |
| Lisinopril | 15 | $68 |
| Prednisone | 18 | $42 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius USA Marketing, Inc.Velphoro | $278 | $31,74417 claims |
| AstraZenecaFarxiga | $1,261 | $18,11417 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 125 nephrology providers in Nevada.
Other nephrology in Las Vegas
- Samuel KantorLas Vegas$319K
- Richard CottieroLas Vegas$220K
- Mark VishnepolskyLas Vegas$68K
- Baishali NairLas Vegas$12K
- Gene OngLas Vegas$11K
- Jeffrey RyuLas Vegas$9K
- Luana PillonLas Vegas$9K
- Lawrence LehrnerLas Vegas$8K
- Hassan OsmanLas Vegas$8K
- Marwan TakieddineLas Vegas$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.